Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication SUPRANE, a general anesthetic, is an inhalation agent indicated: • for induction and/or maintenance of anesthesia in adults ( 1.1 ) • for maintenance of anesthesia in pediatric patients following induction with agents other than SUPRANE and intubation. 1.1 Induction of Anesthesia SUPRANE is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. FDA label
Also known as Suprane, BLM-240
desflurane · 2 trials · 4 indications
Recovery Time after exposure to desflurane or sevoflurane considering time of emergence from anesthesia
The investigator or sub-investigator observed the patient for body movement (excluding bucking) during anesthetic maintenance.
The investigator or sub-investigator observed the patient for the presence or absence of awakening during anesthetic maintenance and interviewed the patient on the day after surgery to confirm whether the patient has any memory during anesthetic maintenance.
Rescue medication includes vasopressors and depressors.
"Rescue medication includes vasopressors and depressors. Percentage of observation points at which systolic pressure 80 to \<150 mmHg and heart rate 50 to \<100 bpm could be maintained "
Rescue medication includes vasopressors and depressors. Percentage of observation points at which no rescue treatment was judged to be required based on blood pressure/heart rate
Evaluation on the efficacy (ability) of BLM-240 as an anesthetic drug.
Evaluation of Awakening/Recovery from Anesthesia from end of study drug inhalation to extubation. The patient was extubated when the following signs were observed:(1) clear consciousness, (2) ability to breathe spontaneously (minute ventilation \>=50 mL/kg/min), and (3) stable circulatory dynamics (systolic pressure: \>=100 mmHg).
| Arm | Type | Description |
|---|---|---|
| Desflurane | ACTIVE_COMPARATOR | Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane. |
| Sevoflurane | ACTIVE_COMPARATOR | Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane. |
| desflurane/N2O | EXPERIMENTAL | - |
| sevoflurane/N2O | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Desflurane | DRUG | 5.4 to 7.4% desflurane |
| Sevoflurane | DRUG | 1.4 to 2.5% Sevoflurane |
| desflurane/nitrous oxide | DRUG | volatile liquid for inhalation with gas for inhalation |
| sevoflurane/nitrous oxide | DRUG | volatile liquid for inhalation and gas for inhalation |
Inclusion Criteria: 1. Male or female, 50 to 75 years of age. 2. Subjects with an American Society of Anesthesiologist (ASA) physical status of I to III. 3. Subjects able to provide written informed consent to participate in the study. 4. Female subjects who have a negative urine or serum pregnancy...
Desflurane is an inhaled anesthetic agent used to induce and maintain general anesthesia during surgical procedures. Its studied uses include anesthesia in adult patients and anesthesia for urological cystoscope surgery. It is a small molecule drug developed by Baxter International Inc. under the ticker BAX.
Desflurane targets potassium channel subunits KCNK10, KCNK18, KCNK2, and KCNK9, as well as the GABA-A receptor subunits GABRA1 and GABRB2. It acts as a channel opener. Activity at these two-pore-domain potassium channels and GABA-A receptors is the basis of its anesthetic mechanism.
Desflurane is developed by Baxter International Inc., which trades under the ticker BAX. Baxter is associated with the Baxter Anaesthesia brand of desflurane studied in clinical research. The drug is a small molecule anesthetic agent in the pain therapeutic area.
Desflurane has been studied in Phase 2 and Phase 3 clinical trials. It is an investigational asset in the development pipeline tracked for Baxter International Inc. Its registered studies are completed, with no active trials currently listed.
Desflurane has been evaluated in two completed trials. NCT01219881 compared desflurane to sevoflurane for recovery time in patients undergoing urological cystoscope surgery in the United States. NCT00762372 was a Japan Phase 2/3 study of BLM-240 (desflurane) in anesthesia, enrolling 216 patients.
Yes, BLM-240 is an alternative name for desflurane. The Japan Phase 2/3 clinical study NCT00762372 was conducted with BLM-240 (desflurane) in patients receiving anesthesia. Readers searching for BLM-240 are looking at the same active agent as desflurane.